Search Patents
  • METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER
    Publication number: 20180119146
    Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.
    Type: Application
    Filed: October 5, 2017
    Publication date: May 3, 2018
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Gerd Helftenbein, Korden Walter, Stefan Wöll, Gabriela-Elena Oprea
  • Methods of producing multispecific antibodies against CD40 and CD137
    Patent number: 11091557
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: August 17, 2021
    Assignees: GENMAB A/S, BioNTech SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • TUMOR ANTIGENS FOR DETERMINING CANCER THERAPY
    Publication number: 20160175414
    Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
    Type: Application
    Filed: July 30, 2014
    Publication date: June 23, 2016
    Inventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Petra Simo, Christoph Hartmann, Stefanie Hubich, Thomas Bukur, Thorsten Litzenberger
  • NOVEL CYTOKINE FUSION PROTEINS
    Publication number: 20180371042
    Abstract: The present invention relates to cytokine fusion proteins and to nucleic acid molecules encoding such cytokine fusion proteins. The present invention further relates to cells, non-human organisms, pharmaceutical compositions and kits comprising the cytokine fusion proteins or the nucleic acid molecules encoding them, as well as to their use as medicaments.
    Type: Application
    Filed: December 16, 2016
    Publication date: December 27, 2018
    Inventors: Ugur SAHIN, Friederike GIESEKE, Sebastian KREITER, Mustafa DIKEN
  • CLAUDIN-18.2-SPECIFIC IMMUNORECEPTORS AND T CELL EPITOPES
    Publication number: 20230303656
    Abstract: The present invention provides Claudin-18.2-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Application
    Filed: June 13, 2023
    Publication date: September 28, 2023
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Oehm, Tana Omokoko, Andrea Breitkreuz, Karolina Anna Mroz, Lisa Hebich
  • RECOMBINANT VACCINES AND USE THEREOF
    Publication number: 20140134201
    Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
    Type: Application
    Filed: January 10, 2014
    Publication date: May 15, 2014
    Applicant: BioNTech AG
    Inventors: Ozlem Tureci, Ugur Sahin, Sebastian Kreiter
  • Selecting Neoepitopes as Disease-Specific Targets for Therapy with Enhanced Efficacy
    Publication number: 20190189241
    Abstract: The present invention relates to methods for determining whether neoepitopes that are only expressed in or on diseased cells are suitable disease-specific targets, such that the diseased cell is less likely to be able to escape immune surveillance, and use of the neoepitopes in providing an immune response against diseased cells expressing the neoepitopes.
    Type: Application
    Filed: July 19, 2017
    Publication date: June 20, 2019
    Inventors: Arbel D. Tadmor, Ugur Sahin
  • Antibodies Against Claudin 18.2 Useful in Cancer Diagnosis
    Publication number: 20150147763
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.
    Type: Application
    Filed: May 6, 2013
    Publication date: May 28, 2015
    Inventors: Ugur Sahin, Özlem Türeci, Rita Mitnacht-Kraus, Stefan Wöll
  • RNA REPLICON FOR REPROGRAMMING SOMATIC CELLS
    Publication number: 20200277627
    Abstract: The present invention embraces a RNA replicon that can be replicated by a replicase of alphavirus origin and comprises an open reading frame encoding a reprogramming factor. Such RNA replicons are useful for expressing a reprogramming factor in a cell, in particular a somatic cell. Cells engineered to express such reprogramming factors are useful in cell transplantation therapies.
    Type: Application
    Filed: September 11, 2018
    Publication date: September 3, 2020
    Inventors: Marco Alexander POLEGANOV, Mario PERKOVIC, Ugur SAHIN, Tim BEISSERT
  • Therapeutic RNA for Treating Cancer
    Publication number: 20240041999
    Abstract: This disclosure relates to the field of therapeutic RNA to treat cancer. Disclosed herein are compositions, uses, and methods for treatment of cancers Administration of therapeutic RNAs to a patient having cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.
    Type: Application
    Filed: December 20, 2021
    Publication date: February 8, 2024
    Inventors: Mathias Vormehr, Lena Mareen Kranz, Ugur Sahin, David Eisel
  • Isolated SCP proteins and uses thereof
    Patent number: 6306389
    Abstract: The invention involves the recognition of a previously unidentified protein family which belongs to, the human SCP family. The members of the family, such as SCP-2 and rat SCP-3 homolog are markers for cell transformation. Diagnostic and therapeutic uses of these protein and related molecules are taught.
    Type: Grant
    Filed: June 8, 2000
    Date of Patent: October 23, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh
  • Coronavirus vaccine
    Patent number: 11878055
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses.
    Type: Grant
    Filed: June 26, 2023
    Date of Patent: January 23, 2024
    Assignee: BioNTech SE
    Inventors: Alexander Muik, Kena Anne Swanson, Qi Yang, Hui Cai, Ugur Sahin, Kayvon Modjarrad
  • ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20220033461
    Abstract: The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.
    Type: Application
    Filed: September 18, 2021
    Publication date: February 3, 2022
    Inventors: Ralf Holger VOSS, Ugur SAHIN, Matthias THEOBALD, Petra SIMON, Matthias BIRTEL
  • USE OF FLT3 LIGAND FOR ENHANCING IMMUNE RESPONSES IN RNA IMMUNIZATION
    Publication number: 20110311584
    Abstract: The invention relates to supplying vaccine RNA to cells. The invention relates in particular to a common use of vaccine RNA and Flt3 ligand for inducing, creating or enhancing an immune response when administered to animals (including humans).
    Type: Application
    Filed: December 9, 2009
    Publication date: December 22, 2011
    Inventors: Ugur Sahin, Özlem Türeci, Sebastian Kreiter, Abderraouf Selmi
  • Multispecific antibodies against CD40 and CD137
    Patent number: 11939388
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: March 26, 2024
    Assignees: GENMAB A/S, BioNTech SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • Identification of Tumor-Associated Antigens for Diagnosis and Therapy
    Publication number: 20140017254
    Abstract: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
    Type: Application
    Filed: July 19, 2013
    Publication date: January 16, 2014
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Dirk Usener
  • ANTIBODY AND TAXANE COMBINATION THERAPY
    Publication number: 20240109972
    Abstract: The present invention provides combination therapy to reduce or prevent progression of a tumor or treating cancer in a subject. The combination therapy comprises administration of a binding agent that binds to human CD137 and to human PD-L1; and a taxane chemotherapeutic agent.
    Type: Application
    Filed: December 7, 2021
    Publication date: April 4, 2024
    Inventors: Ugur SAHIN, Alexander MUIK, Ulf FORSSMANN, Maria JURE-KUNKEL, Manish GUPTA, Tahamtan AHMADI, Kathy AMIRI, Gaurav BAJAJ
  • Identification of tumor-associated antigens for diagnosis and therapy
    Patent number: 8975375
    Abstract: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: March 10, 2015
    Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-Universitat
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Dirk Usener
  • ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20180282390
    Abstract: The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.
    Type: Application
    Filed: October 5, 2016
    Publication date: October 4, 2018
    Inventors: Ralf Holger VOSS, Ugur SAHIN, Matthias THEOBALD, Petra SIMON, Matthias BIRTEL
  • Methods and compositions for diagnosis and treatment of cancer
    Patent number: 9637548
    Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of colorectal, in particular colonic, and gastric tumor tissues and colorectal, in particular colonic, and gastric tissues, and which represent targets for therapy or diagnosis of such tumor diseases in a subject.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: May 2, 2017
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITAT MAINZ
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
Narrow Results

Filter by US Classification